Class III SLRP agonists for the reduction of blood vessel formation

Research output: Patent

Abstract

Patent protecting the use of opticin, other class III SLRPs or fragments thereof as therapeutic inhibitors of angiogenesis

Bibliographical metadata

Original languageEnglish
Patent numberUS7358224
Publication statusPublished - 15 Apr 2008